Over the counter availability of inhalers
Pro Research Analysisby 
Searched over 200M research papers
Over-the-Counter Inhalers: Access and Asthma Management
OTC Inhaler Availability and Asthma Undertreatment
Research shows that when inhalers, especially beta-2 agonists like salbutamol, are available over the counter (OTC), there is a higher risk of asthma undertreatment. People who buy inhalers without a prescription are less likely to see a doctor regularly, which leads to less optimal asthma management and more frequent undertreatment compared to those who get inhalers by prescription. This pattern is seen even when the severity of asthma is similar between groups, and the risk of undertreatment is significantly higher among OTC purchasers, especially if they also smoke or do not use peak flow meters to monitor their asthma 14.
Patterns of Use and Asthma Outcomes with OTC Inhalers
Easy access to OTC inhalers can lead to overuse, especially of short-acting beta-2 agonists (SABA). Studies from Australia, where SABA inhalers are available both OTC and by prescription, show that people who use more than three inhalers a year are much more likely to have poor asthma control and more severe asthma attacks. Many people who buy inhalers OTC do not use other recommended asthma medications, such as inhaled corticosteroids, which further increases their risk of poor outcomes. The disconnect between what is prescribed, what is bought OTC, and what is actually used makes it hard for healthcare providers to track and manage asthma effectively 14.
Safety and Risks of OTC Inhalers
OTC inhalers, such as those containing epinephrine, are generally safe for people with mild, intermittent asthma if used as directed. However, misuse or overuse can cause serious side effects, including death. Surveys indicate that a significant number of people using OTC inhalers actually have more persistent asthma and should be under a doctor’s care, receiving more comprehensive treatment like corticosteroids. There is concern that OTC access may encourage self-management without proper medical oversight, increasing the risk of complications and poor asthma control 35.
Regulatory Perspectives and Recommendations
There is ongoing debate about making more effective inhaler therapies, such as inhaled corticosteroid (ICS)/formoterol combinations, available OTC. Evidence suggests that ICS/formoterol reliever therapy is safer and more effective than SABA alone, reducing the risk of severe asthma attacks and overuse of beta-agonists. Making these combination inhalers available OTC could improve access, especially for disadvantaged groups, and lead to better asthma outcomes. However, there are regulatory barriers, especially in the United States, where these products are not yet approved for OTC use. Experts argue that shifting to OTC ICS/formoterol could reduce asthma-related deaths and healthcare costs, but safety and proper use must be ensured .
Recent Developments in OTC Inhalers
The return of products like Primatene Mist, an OTC inhaler for mild, intermittent asthma, highlights the ongoing demand for non-prescription options. These products are now approved for use in people aged 12 and older, but their administration techniques and safety profiles differ from prescription inhalers. Proper education on their use is essential to avoid misuse and potential harm 23.
Conclusion
While OTC availability of inhalers increases access, it is linked to higher rates of undertreatment, overuse, and poor asthma control, especially when not paired with regular medical supervision. Safer and more effective therapies, such as ICS/formoterol combinations, could offer better outcomes if made available OTC, but careful regulation and patient education are crucial to minimize risks and ensure proper asthma management 1345+1 MORE.
Sources and full results
Most relevant research papers on this topic